Loading
This study tests a PARP inhibitor; the registry reports that it is active not recruiting.
The registry lists NCT05367440 as active not recruiting, last updated 2026-08-26. Enrolment is 174 actual participants. Interventions: AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide. Primary measures include Number of patients with Adverse Events and Serious Adverse Events; Part A: Number of patients with Dose Limiting Toxicities (DLTs). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Darolutamide, Apalutamide, Abiraterone acetate, Enzalutamide.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, Prostate cancer.
Shares Saruparib, PARP, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Saruparib, PARP, AstraZeneca, Prostate cancer.
Shares Saruparib, PARP, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/